AtriCure, Inc.
ATRCHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 26, 2026
Scan Results
Daily timeframeAtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral. The company carries a $3.00B market cap, placing it firmly in the mid-cap category. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.
Market Cap
$3.00B
Beta
1.25
P/E (TTM)
280.81
P/E (Fwd)
135.88
EPS (TTM)
$0.21
EPS (Fwd)
$0.43
ROE
2.1%
ROA
1.3%
Cash
$167.8M
Total Debt
$74.2M
Free CF
$48.8M
52W Change
61.7%
Annual Financials
Cash vs Debt
Where ATRC stands vs its 150-day and 200-day moving averages
As of the September 30, 2026 close, ATRC finished 63.61% above its 150-day moving average ($35.48) and 60.63% above its 200-day moving average ($36.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATRC overbought or oversold?
At the September 30, 2026 close, ATRC's RSI(14) was 69.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $167.8M in cash comfortably exceeding the $74.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $48.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 2.1%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $330.4M (2022) to $534.5M (2025), reflecting a 62% increase over the period.
With cash comfortably exceeding debt, ATRC has financial flexibility that may help navigate uncertain periods. At over 50x earnings, ATRC carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ATRC.